Nitric oxide, NAD(P)H oxidase, and atherosclerosis

Antioxidants and Redox Signaling

Volumn 11, Issue 7, 2009, Pages 1711-1731

  Muller, Gregor ^a   Morawietz, Henning ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; MINERALOCORTICOID ANTAGONIST; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROBUCOL; PROTEIN DUOX1; PROTEIN DUOX2; PROTEIN P22PHOX; PROTEIN P47PHOX; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; COMPLEX FORMATION; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; ATHEROSCLEROSIS; HUMANS; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 66849135266     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2008.2403     Document Type: Review

References (249)

1. Adams V, Linke A, Krankel N, Erbs S, Gielen S, Mobius-Winkler S, Gummert JF, Mohr FW, Schuler G, and Hambrecht R. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 111: 555-562, 2005.
2. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, and Iida M. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109: 227-233, 2004.
3. Al-Benna S, Hamilton CA, McClure JD, Rogers PN, Berg GA, Ford I, Delles C, and Dominiczak AF. Low-density lipoprotein cholesterol determines oxidative stress and endothelial dysfunction in saphenous veins from patients with coronary artery disease. Arterioscler Thromb Vasc Biol 26: 218-223, 2006.
4. Ambasta RK, Schreiber JG, Janiszewski M, Busse R, and Brandes RP. Noxa1 is a central component of the smooth muscle NADPH oxidase in mice. Free Radic Biol Med 41: 193-201, 2006.
5. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, and Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 279: 45935-45941, 2004.
6. 2-generating activity. J Biol Chem 280: 30046-30054, 2005.
7. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, and Luscher TF. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial. Lancet 364: 347-354, 2004.
8. Ayajiki K, Kindermann M, Hecker M, Fleming I, and Busse R. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res 78: 750-758, 1996.
9. Balakumar P, Rose M, and Singh M. PPAR ligands: Are they potential agents for cardiovascular disorders? Pharmacology 80: 1-10, 2007.
10. Banfi B, Clark RA, Steger K, and Krause KH. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 278: 3510-3513, 2003.
11. Banfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, and Krause KH. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 279: 46065-46072, 2004.
12. 2+-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 276: 37594-37601, 2001.
13. 2+ activation of the NADPH oxidase 5 (NOX5). J Biol Chem 279: 18583-18591, 2004.
14. + channel generated through alternative splicing of the NADPH oxidase homolog NOH-1. Science 287: 138-142, 2000.
15. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, and Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 108: 1513-1522, 2001.
16. A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 95: 14367-14372, 1998.
17. Bayraktutan U. Nitric oxide synthase and NAD(P)H oxidase modulate coronary endothelial cell growth. J Mol Cell Cardiol 36: 277-286, 2004.
18. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007.
19. BelAiba RS, Djordjevic T, Petry A, Diemer K, Bonello S, Banfi B, Hess J, Pogrebniak A, Bickel C, and Gorlach A. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med 42: 446-459, 2007.
20. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, and Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: Angiotensin II increases superoxide production in human internal mammary arteries. Circulation 101: 2206-2212, 2000.
21. Bohm F, Beltran E, and Pernow J. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J Intern Med 257: 263-271, 2005.
22. Braam B and Verhaar MC. Understanding eNOS for pharmacological modulation of endothelial function: A translational view. Curr Pharm Des 13: 1727-1740, 2007.
23. Brar SS, Corbin Z, Kennedy TP, Hemendinger R, Thornton L, Bommarius B, Arnold RS, Whorton AR, Sturrock AB, Huecksteadt TP, Quinn MT, Krenitsky K, Ardie KG, Lambeth JD, and Hoidal JR. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol 285: C353-369, 2003.
24. Busse R and Fleming I. Pulsatile stretch and shear stress: Physical stimuli determining the production of endothelium-derived relaxing factors. J Vasc Res 35: 73-84, 1998.
25. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 96: 818-822, 2005.
26. Cai H, Griendling KK, and Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24: 471-478, 2003.
27. Calnek DS, Mazzella L, Roser S, Roman J, and Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23: 52-57, 2003.
28. Cardillo C, Kilcoyne CM, Cannon RO, 3rd, Quyyumi AA, and Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 30: 57-63, 1997.
29. Carnevale R, Pignatelli P, Lenti L, Buchetti B, Sanguigni V, Di Santo S, and Violi F. LDL are oxidatively modified by platelets via GP91(phox) and accumulate in human monocytes. FASEB J 21: 927-934, 2007.
30. Castier Y, Brandes RP, Leseche G, Tedgui A, and Lehoux S. p47phox-dependent NADPH oxidase regulates flow-induced vascular remodeling. Circ Res 97: 533-540, 2005.
31. Ceriello A and Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24: 816-823, 2004.
32. Chello M, Mastroroberto P, Perticone F, Celi V, and Colonna A. Nitric oxide modulation of neutrophil-endothelium interaction: Difference between arterial and venous coronary bypass grafts. J Am Coll Cardiol 31: 823-826, 1998.
33. Chen H, Li D, Sawamura T, Inoue K, and Mehta JL. Up-regulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: Modulation by losartan. Biochem Biophys Res Commun 276: 1100-1104, 2000.
34. Cheng G and Lambeth JD. NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox homology (PX) domain. J Biol Chem 279: 4737-4742, 2004.
35. Cheng G and Lambeth JD. Alternative mRNA splice forms of NOXO1: differential tissue expression and regulation of Nox1 and Nox3. Gene 356: 118-126, 2005.
36. Cheng G, Cao Z, Xu X, van Meir EG, and Lambeth JD. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 269: 131-140, 2001.
37. Chevrier I, Tregouet DA, Massonnet-Castel S, Beaune P, and Loriot MA. Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: Genetic determinants for atherosclerosis? Atherosclerosis 188: 150-154, 2006.
38. Cifuentes ME and Pagano PJ. Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 15: 179-186, 2006.
39. Cui XL, Brockman D, Campos B, and Myatt L. Expression of NADPH oxidase isoform 1 (Nox1) in human placenta: involvement in preeclampsia. Placenta 27: 422-431, 2006.
40. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, and Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87: 5134-5138, 1990.
41. Darley-Usmar VM, Hogg N, O'Leary VJ, Wilson MT, and Moncada S. The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic Res Commun 17: 9-20, 1992.
42. Das SK and Chakrabarti R. Role of PPAR in cardiovascular diseases. Recent Patents Cardiovasc Drug Discov 1: 193-209, 2006.
43. Davenport AP and Maguire JJ. Endothelin. Handb Exp Pharmacol: 295-329, 2006.
44. De Deken X, Wang D, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE, and Miot F. Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem 275: 23227-23233, 2000.
45. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, and Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 329: 653-657, 1998.
46. De Keulenaer GW, Chappell DC, Ishizaka N, Nerem RM, Alexander RW, and Griendling KK. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. Circ Res 82: 1094-1101, 1998.
47. DeLeo FR, Burritt JB, Yu L, Jesaitis AJ, Dinauer MC, and Nauseef WM. Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly. J Biol Chem 275: 13986-13993, 2000.
48. Dendorfer A, Dominiak P, and Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol: 407-442, 2005.
49. Diodati JG, Dakak N, Gilligan DM, and Quyyumi AA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 98: 17-24, 1998.
50. B receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145: 323-333, 2005.
51. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
52. Duerrschmidt N and Morawietz H. NO-dependent down-regulation of NAD(P)H oxidase by arterial laminar shear stress in human endothelial cells. Circulation 106 (Suppl.): II-272-II-273, 2002.
53. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, and Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 269: 713-717, 2000.
54. Duerrschmidt N, Stielow C, Muller G, Pagano PJ, and Morawietz H. NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells. J Physiol 576: 557-567, 2006.
55. Duprez DA. Aldosterone and the vasculature: Mechanisms mediating resistant hypertension. J Clin Hypertens 9: 13-18, 2007.
56. Eklund EA and Kakar R. Recruitment of CREB-binding protein by PU.1, IFN-regulatory factor-1, and the IFN consensus sequence-binding protein is necessary for IFN-gamma-induced p67phox and gp91phox expression. J Immunol 163: 6095-6105, 1999.
57. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, and Machado RA. Endothelial dysfunction: A comprehensive appraisal. Cardiovasc Diabetol 5: 4, 2006.
58. Fiebeler A and Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev 10: 47-52, 2005.
59. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 18: 20-25, 2008.
60. Fleming I and Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284: R1-12, 2003.
61. Forstermann U. Janus-faced role of endothelial NO synthase in vascular disease: Uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 387: 1521-1533, 2006.
62. Forstermann U and Munzel T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 113: 1708-1714, 2006.
63. Forstermann U, Mugge A, Alheid U, Haverich A, and Frolich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 62: 185-190, 1988.
64. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers QT, Taylor WR, Harrison DG, de Leon H, Wilcox JN, and Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997.
65. Funder JW. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 7: 151-157, 2007.
66. Furchgott RF and Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980.
67. Garg UC and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774-1777, 1989.
68. Gauss KA, Bunger PL, and Quinn MT. AP-1 is essential for p67(phox) promoter activity. J Leukoc Biol 71: 163-172, 2002.
69. Geiszt M, Kopp JB, Varnai P, and Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97: 8010-8014, 2000.
70. Ghiadoni L, Virdis A, Magagna A, Taddei S, and Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 35: 501-506, 2000.
71. Gimbrone MA, Jr., Topper JN, Nagel T, Anderson KR, and Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci 902: 230-239, 2000.
72. Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci 360: 2259-2272, 2005.
73. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, and Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 87: 26-32, 2000.
74. 2+ influx and activation of the neutrophil respiratory burst. Different regulation of plasma membrane- and granule-localized NADPH-oxidase. J Leukoc Biol 71: 611-617, 2002.
75. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
76. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
77. Griendling KK, Sorescu D, Lassegue B, and Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183, 2000.
78. Gryglewski RJ, Palmer RM, and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320: 454-456, 1986.
79. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, and Channon KM. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 86: E85-90, 2000.
80. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, and Channon KM. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 102: 1744-1747, 2000.
81. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, Korbut R, and Channon KM. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 24: 1614-1620, 2004.
82. Hagg D, Englund MC, Jernas M, Schmidt C, Wiklund O, Hulten LM, Ohlsson BG, Carlsson LM, Carlsson B, and Svensson PA. Oxidized LDL induces a coordinated up-regulation of the glutathione and thioredoxin systems in human macrophages. Atherosclerosis 185: 282-289, 2006.
83. Harper RW, Xu C, Eiserich JP, Chen Y, Kao CY, Thai P, Setiadi H, and Wu R. Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cytokines in respiratory tract epithelium. FEBS Lett 579: 4911-4917, 2005.
84. Harrison R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev 36: 363-375, 2004.
85. Hathaway CA, Heistad DD, Piegors DJ, and Miller FJ, Jr. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 90: 277-283, 2002.
86. Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, and Kasai K. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 27: 865-870, 2007.
87. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RA, Macharzina R, Brasen JH, Meinertz T, and Munzel T. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: Evidence for an involvement of protein kinase C. Kidney Int 55: 252-260, 1999.
88. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, and Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 677-683, 2004.
89. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, and Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367-1373, 1993.
90. Hishikawa K and Luscher TF. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation 96: 3610-3616, 1997.
91. Hollenberg NK. The renin system: Is direct renin inhibition different from blockade at the AT1 receptor or the ACE step? Rev Cardiovasc Med 8 Suppl 2: S7-13, 2007.
92. Honbou K, Minakami R, Yuzawa S, Takeya R, Suzuki NN, Kamakura S, Sumimoto H, and Inagaki F. Full-length p40phox structure suggests a basis for regulation mechanism of its membrane binding. EMBO J 26: 1176-1186, 2007.
93. Hsiai TK, Hwang J, Barr ML, Correa A, Hamilton R, Alavi M, Rouhanizadeh M, Cadenas E, and Hazen SL. Hemodynamics influences vascular peroxynitrite formation: Implication for low-density lipoprotein apo-B-100 nitration. Free Radic Biol Med 42: 519-529, 2007.
94. Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, and Finkel T. Vascular effects following homozygous disruption of p47(phox): An essential component of NADPH oxidase. Circulation 101: 1234-1236, 2000.
95. Hsieh HJ, Cheng CC, Wu ST, Chiu JJ, Wung BS, and Wang DL. Increase of reactive oxygen species (ROS) in endothelial cells by shear flow and involvement of ROS in shear-induced c-fos expression. J Cell Physiol 175: 156-162, 1998.
96. Hwang J, Wang J, Morazzoni P, Hodis HN, and Sevanian A. The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: An antioxidant mechanism for cell-mediated LDL modification. Free Radic Biol Med 34: 1271-1282, 2003.
97. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, and Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 288: C899-905, 2005.
98. Hwang J, Ing MH, Salazar A, Lassegue B, Griendling K, Navab M, Sevanian A, and Hsiai TK. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: Implication for native LDL oxidation. Circ Res 93: 1225-1232, 2003.
99. 2 from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem 278: 47291-47298, 2003.
100. Inagi R. Oxidative stress in cardiovascular disease: a new avenue toward future therapeutic approaches. Recent Patents Cardiovasc Drug Discov 1: 151-159, 2006.
101. Itoh S, Umemoto S, Hiromoto M, Toma Y, Tomochika Y, Aoyagi S, Tanaka M, Fujii T, and Matsuzaki M. Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. Circulation 105: 2288-2295, 2002.
102. Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, and Matsumoto T. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 92: 81-87, 2003.
103. Iwano S, Asanuma F, Nukaya M, Saito T, and Kamataki T. CYP1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 337: 708-712, 2005.
104. Jacobi J, Kristal B, Chezar J, Shaul SM, and Sela S. Exogenous superoxide mediates pro-oxidative, proinflammatory, and procoagulatory changes in primary endothelial cell cultures. Free Radic Biol Med 39: 1238-1248, 2005.
105. Jialal I and Devaraj S. Antioxidants and atherosclerosis: Don't throw out the baby with the bath water. Circulation 107: 926-928, 2003.
106. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, and Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 271: H1626-H1634, 1996.
107. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, and Brandes RP. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109: 1795-1801, 2004.
108. Kalinina N, Agrotis A, Tararak E, Antropova Y, Kanellakis P, Ilyinskaya O, Quinn MT, Smirnov V, and Bobik A. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 22: 2037-2043, 2002.
109. Kanai F, Liu H, Field SJ, Akbary H, Matsuo T, Brown GE, Cantley LC, and Yaffe MB. The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat Cell Biol 3: 675-678, 2001.
110. Karlsson A and Dahlgren C. Assembly and activation of the neutrophil NADPH oxidase in granule membranes. Antioxid Redox Signal 4: 49-60, 2002.
111. Kaysen GA and Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15: 538-548, 2004.
112. Keller M, Lidington D, Vogel L, Peter BF, Sohn HY, Pagano PJ, Pitson S, Spiegel S, Pohl U, and Bolz SS. Sphingosine kinase functionally links elevated transmural pressure and increased reactive oxygen species formation in resistance arteries. FASEB J 20: 702-704, 2006.
113. Kelm M. The L-arginine-nitric oxide pathway in hypertension. Curr Hypertens Rep 5: 80-86, 2003.
114. Khan BV, Harrison DG, Olbrych MT, Alexander RW, and Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 93: 9114-9119, 1996.
115. Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ, McAlister FA, Rabkin SW, Hill MD, Feldman RD, Schiffrin EL, Campbell NR, Logan AG, Arnold M, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Leiter LA, Ogilvie RI, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Burns KD, Ruzicka M, de-Champlain J, Pylypchuk G, Gledhill N, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Touyz RM, and Tobe SW. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol 23: 539-550, 2007.
116. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, and LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 20: 1529-1535, 2000.
117. Kita T. LOX-1, a possible clue to the missing link between hypertension and atherogenesis. Circ Res 84: 1113-1115, 1999.
118. Kobayashi N, Yoshida K, Mita S, Honda T, Hara K, Nakano S, Tsubokou Y, and Matsuoka H. Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats. J Hypertens 22: 1397-1402, 2004.
119. Kobayashi S, Nojima Y, Shibuya M, and Maru Y. Nox1 regulates apoptosis and potentially stimulates branching morphogenesis in sinusoidal endothelial cells. Exp Cell Res 300: 455-462, 2004.
120. Krotz F, Engelbrecht B, Buerkle MA, Bassermann F, Bridell H, Gloe T, Duyster J, Pohl U, and Sohn HY. The tyrosine phosphatase, SHP-1, is a negative regulator of endothelial superoxide formation. J Am Coll Cardiol 45: 1700-1706, 2005.
121. Krug AW, Kopprasch S, Ziegler CG, Dippong S, Catar RA, Bornstein SR, Morawietz H, and Gekle M. Aldosterone rapidly induces leukocyte adhesion to endothelial cells: A new link between aldosterone and arteriosclerosis? Hypertension 50: e156-157, 2007.
122. Kume N, Cybulsky MI, and Gimbrone MA, Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90: 1138-1144, 1992.
123. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, and Luno J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Curr Med Chem 14: 243-248, 2007.
124. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4: 181-189, 2004.
125. Lambeth JD, Cheng G, Arnold RS, and Edens WA. Novel homologs of gp91phox. Trends Biochem. Sci. 25: 459-461, 2000.
126. Landmesser U, Hornig B, and Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation 109: II27-33, 2004.
127. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, and Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209, 2003.
128. Lapouge K, Smith SJ, Groemping Y, and Rittinger K. Architecture of the p40-p47-p67phox complex in the resting state of the NADPH oxidase. A central role for p67phox. J Biol Chem 277: 10121-10128, 2002.
129. Lassegue B and Griendling KK. Nox is playing with a full deck in vascular smooth muscle, a commentary on "Noxa1 is a central component of the smooth muscle NADPH oxidase in mice". Free Radic Biol Med 41: 185-187, 2006.
130. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, and Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88: 888-894, 2001.
131. Laufs U, La Fata V, Plutzky J, and Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998.
132. Laufs U, Wassmann S, Czech T, Munzel T, Eisenhauer M, Bohm M, and Nickenig G. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc Biol 25: 809-814, 2005.
133. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, and Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Pharmacol Ther 83: 52-60, 2008.
134. Lehoux S. Redox signalling in vascular responses to shear and stretch. Cardiovasc Res 71: 269-279, 2006.
135. Lehoux S, Esposito B, Merval R, Loufrani L, and Tedgui A. Pulsatile stretch-induced extracellular signal-regulated kinase 1/2 activation in organ culture of rabbit aorta involves reactive oxygen species. Arterioscler Thromb Vasc Biol 20: 2366-2372, 2000.
136. Leite PF, Liberman M, Sandoli de Brito F, and Laurindo FR. Redox processes underlying the vascular repair reaction. World J Surg 28: 331-336, 2004.
137. Leto TL, Adams AG, and de Mendez I. Assembly of the phagocyte NADPH oxidase: Binding of Src homology 3 domains to proline-rich targets. Proc Natl Acad Sci USA 91: 10650-10654, 1994.
138. Li DY, Zhang YC, Philips MI, Sawamura T, and Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 84: 1043-1049, 1999.
139. Li JM and Shah AM. Endothelial cell superoxide generation: Regulation and relevance for cardiovascular patho-physiology. Am J Physiol Regul Integr Comp Physiol 287: R1014-1030, 2004.
140. Li SL, Valente AJ, Zhao SJ, and Clark RA. PU.1 is essential for p47(phox) promoter activity in myeloid cells. J Biol Chem 272: 17802-17809, 1997.
141. Li SL, Valente AJ, Qiang M, Schlegel W, Gamez M, and Clark RA. Multiple PU.1 sites cooperate in the regulation of p40(phox) transcription during granulocytic differentiation of myeloid cells. Blood 99: 4578-4587, 2002.
142. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipo-protein cholesterol. Am J Cardiol 96: 24F-33F, 2005.
143. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, and Teo K. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103: 919-925, 2001.
144. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 10 Suppl 1: S49-57, 2005.
145. Madamanchi NR and Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res 100: 460-473, 2007.
146. Malech HL and Hickstein DD. Genetics, biology and clinical management of myeloid cell primary immune deficiencies: Chronic granulomatous disease and leukocyte adhesion deficiency. Curr Opin Hematol 14: 29-36, 2007.
147. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, and Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18: 69-82, 2006.
148. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: Review of the evidence. Atherosclerosis 165: 191-199, 2002.
149. Matsui R, Xu S, Maitland KA, Mastroianni R, Leopold JA, Handy DE, Loscalzo J, and Cohen RA. Glucose-6-phosphate dehydrogenase deficiency decreases vascular superoxide and atherosclerotic lesions in apolipoprotein E(-/-) mice. Arterioscler Thromb Vasc Biol 26: 910-916, 2006.
150. Matsunaga T, Nakajima T, Miyazaki T, Koyama I, Hokari S, Inoue I, Kawai S, Shimomura H, Katayama S, Hara A, and Komoda T. Glycated high-density lipoprotein regulates reactive oxygen species and reactive nitrogen species in endothelial cells. Metabolism 52: 42-49, 2003.
151. McCormick ML, Gavrila D, and Weintraub NL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 27: 461-469, 2007.
152. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, and Harrison DG. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285: H2290-2297, 2003.
153. Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 17: 552-558, 2002.
154. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, and Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90: E58-65, 2002.
155. Morawietz H. Antioxidative defense in endothelial cells: New kids on the block. Thromb Haemost 97: 3-4, 2007.
156. Morawietz H. Going with the flow: Just say NO to oxygen radicals. Physiology News 66: 30-31, 2007.
157. Morawietz H, Duerrschmidt N, Niemann B, Galle J, Sawamura T, and Holtz J. Induction of the oxLDL receptor LOX-1 by endothelin-1 in human endothelial cells. Biochem Biophys Res Commun 284: 961-965, 2001.
158. Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, and Holtz J. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 100: 899-902, 1999.
159. 1 blockade and cholesterol-dependent oxidative stress: The EPAS trial. Circulation 114: I296-1301, 2006.
160. Moreno MU, San Jose G, Orbe J, Paramo JA, Beloqui O, Diez J, and Zalba G. Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett 542: 27-31, 2003.
161. Motte S, McEntee K, and Naeije R. Endothelin receptor antagonists. Pharmacol Ther 110: 386-414, 2006.
162. Muller G, Catar RA, Niemann B, Barton M, Knels L, Wendel M, and Morawietz H. Upregulation of endothelin receptor B in human endothelial cells by low-density lipo-proteins. Exp Biol Med 231: 766-771, 2006.
163. Munzel T, Hink U, Heitzer T, and Meinertz T. Role for NADPH/NADH oxidase in the modulation of vascular tone. Ann NY Acad Sci 874: 386-400, 1999.
164. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 355: 2003-2011, 2006.
165. Napoli C, Ackah E, De Nigris F, Del Soldato P, D'Armiento FP, Crimi E, Condorelli M, and Sessa WC. Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proc Natl Acad Sci USA 99: 12467-12470, 2002.
166. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, and Fierro IM. Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: A novel antioxidative mechanism. Thromb Haemost 97: 88-98, 2007.
167. Niemann B, Rohrbach S, Catar RA, Muller G, Barton M, and Morawietz H. Native and oxidized low-density lipo-proteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells. Biochem Biophys Res Commun 334: 747-753, 2005.
168. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM, Alexander RW, and Murphy TJ. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 90: 2092-2096, 1992.
169. Ohara Y, Peterson TE, and Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551, 1993.
170. Orosz Z, Csiszar A, Labinskyy N, Smith K, Kaminski PM, Ferdinandy P, Wolin MS, Rivera A, and Ungvari Z. Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: Role of NAD(P)H oxidase activation. Am J Physiol Heart Circ Physiol 292: H130-139, 2007.
171. Pachucki J, Wang D, Christophe D, and Miot F. Structural and functional characterization of the two human ThOX/Duox genes and their 5′-flanking regions. Mol Cell Endocrinol 214: 53-62, 2004.
172. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, and Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100: 2312-2318, 1999.
173. Parkos CA, Allen RA, Cochrane CG, and Jesaitis AJ. Purified cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000. J Clin Invest 80: 732-742, 1987.
174. Patrono C and Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 28: s25-32, 2008.
175. Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, and Gorlach A. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal 8: 1473-1484, 2006.
176. Pohl U, Holtz J, Busse R, and Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 8: 37-44, 1986.
177. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J, Orkin SH, Doerschuk CM, and Dinauer MC. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 9: 202-209, 1995.
178. Radmark O and Samuelsson B. 5-lipoxygenase: Regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat 83: 162-174, 2007.
179. Radomski MW, Palmer RM, and Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148: 1482-1489, 1987.
180. Rajagopalan S, Duquaine D, King S, Pitt B, and Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 2212-2216, 2002.
181. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
182. Rask-Madsen C and King GL. Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3: 46-56, 2007.
183. + flux. Nature 416: 291-297, 2002.
184. Rey FE and Pagano PJ. The reactive adventitia: Fibroblast oxidase in vascular function. Arterioscler Thromb Vasc Biol 22: 1962-1971, 2002.
185. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, Capra V, and D'Orazio N. The role of the antioxidant vitamin supplementation in the prevention of cardiovascular diseases. Expert Opin Investig Drugs 16: 25-32, 2007.
186. Riccioni G, Bucciarelli T, Mancini B, Corradi F, Di Ilio C, Mattei PA, and D'Orazio N. Antioxidant vitamin supplementation in cardiovascular diseases. Ann Clin Lab Sci 37: 89-95, 2007.
187. Ris-Stalpers C. Physiology and pathophysiology of the DUOXes. Antioxid Redox Signal 8: 1563-1572, 2006.
188. Royer-Pokora B, Kunkel LM, Monaco AP, Goff SC, Newburger PE, Baehner RL, Cole FS, Curnutte JT, and Orkin SH. Cloning the gene for an inherited human disorder - chronic granulomatous disease - on the basis of its chromosomal location. Nature 322: 32-38, 1986.
189. Rueckschloss U, Duerrschmidt N, and Morawietz H. NADPH oxidase in endothelial cells: Impact on atherosclerosis. Antioxid. Redox Signal. 5: 171-180, 2003.
190. Rueckschloss U, Quinn MT, Holtz J, and Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: Protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22: 1845-1851, 2002.
191. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, and Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: Anti-oxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104: 1767-1772, 2001.
192. Sanz-Rosa D, Oubina MP, Cediel E, De las Heras N, Aragoncillo P, Balfagon G, Cachofeiro V, and Lahera V. Eplerenone reduces oxidative stress and enhances eNOS in SHR: Vascular functional and structural consequences. Antioxid Redox Signal 7: 1294-1301, 2005.
193. Schieffer B and Drexler H. Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. Am J Cardiol 91: 12H-18H, 2003.
194. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 47: 312-318, 2006.
195. Schiffrin EL, Park JB, Intengan HD, and Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101: 1653-1659, 2000.
196. Schmieder RE, Hilgers KF, Schlaich MP, and Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 369: 1208-1219, 2007.
197. Schulman IH, Zhou MS, and Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: Role in atherosclerosis and hypertension. J Hypertens Suppl 24: S45-50, 2006.
198. Segal BH, Leto TL, Gallin JI, Malech HL, and Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine 79: 170-200, 2000.
199. Serrander L, Jaquet V, Bedard K, Plastre O, Hartley O, Arnaudeau S, Demaurex N, Schlegel W, and Krause KH. NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. Biochimie 89: 1159-1167, 2007.
200. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Forro L, Schlegel W, and Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406: 105-114, 2007.
201. Sethi AS, Lees DM, Douthwaite JA, Dawnay AB, and Corder R. Homocysteine-induced endothelin-1 release is dependent on hyperglycaemia and reactive oxygen species production in bovine aortic endothelial cells. J Vasc Res 43: 175-183, 2006.
202. Shatrov VA, Sumbayev VV, Zhou J, and Brune B. Oxidized low-density lipoprotein (oxLDL) triggers hypoxiainducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood 101: 4847-4849, 2003.
203. Shaul PW. Regulation of endothelial nitric oxide synthase: Location, location, location. Annu Rev Physiol 64: 749-774, 2002.
204. Shiose A, Kuroda J, Tsuruya K, Hirai M, Hirakata H, Naito S, Hattori M, Sakaki Y, and Sumimoto H. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 276: 1417-1423, 2001.
205. Shirodaria C, Antoniades C, Lee J, Jackson CE, Robson MD, Francis JM, Moat SJ, Ratnatunga C, Pillai R, Refsum H, Neubauer S, and Channon KM. Global improvement of vascular function and redox state with low-dose folic acid: Implications for folate therapy in patients with coronary artery disease. Circulation 115: 2262-2270, 2007.
206. Silver AE, Beske SD, Christou DD, Donato AJ, Moreau KL, Eskurza I, Gates PE, and Seals DR. Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. Circulation 115: 627-637, 2007.
207. Siow YL, Au-Yeung KK, Woo CW, and O K. Homocysteine stimulates phosphorylation of NADPH oxidase p47phox and p67phox subunits in monocytes via protein kinase Cbeta activation. Biochem J 398: 73-82, 2006.
208. Sohn HY, Keller M, Gloe T, Morawietz H, Rueckschloss U, and Pohl U. The small G-protein Rac mediates depolarization-induced superoxide formation in human endothelial cells. J Biol Chem 275: 18745-18750, 2000.
209. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, and Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429-1435, 2002.
210. Steer KA, Wallace TM, Bolton CH, and Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart 77: 333-337, 1997.
211. Stielow C, Müller G, and Morawietz H. Nox4-mediated superoxide anion formation in human endothelial cells. J Vasc Res 43: 28-29, 2006.
212. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH, and Morawietz H. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 344: 200-205, 2006.
213. Strawn WB, Chappell MC, Dean RH, Kivlighn S, and Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 101: 1586-1593, 2000.
214. Szasz T, Thakali K, Fink GD, and Watts SW. A comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease. Exp Biol Med 232: 27-37, 2007.
215. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, and Miyazaki M. Eplerenone inhibits atherosclerosis in non-human primates. Hypertension 46: 1135-1139, 2005.
216. Takaya T, Hirata K, Yamashita T, Shinohara M, Sasaki N, Inoue N, Yada T, Goto M, Fukatsu A, Hayashi T, Alp NJ, Channon KM, Yokoyama M, and Kawashima S. A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol 27: 1632-1637, 2007.
217. Takayama T, Wada A, Tsutamoto T, Ohnishi M, Fujii M, Isono T, and Horie M. Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J 68: 1067-1075, 2004.
218. Takeya R, Ueno N, Kami K, Taura M, Kohjima M, Izaki T, Nunoi H, and Sumimoto H. Novel human homo-logues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem 278: 25234-25246, 2003.
219. Thakali KM, Lau Y, Fink GD, Galligan JJ, Chen AF, and Watts SW. Mechanisms of hypertension induced by nitric oxide (NO) deficiency: Focus on venous function. J Cardiovasc Pharmacol 47: 742-750, 2006.
220. Thomas SR, Chen K, and Keaney JF Jr. Oxidative stress and endothelial nitric oxide bioactivity. Antioxid Redox Signal 5: 181-194, 2003.
221. Torzewski M, Ochsenhirt V, Kleschyov AL, Oelze M, Daiber A, Li H, Rossmann H, Tsimikas S, Reifenberg K, Cheng F, Lehr HA, Blankenberg S, Forstermann U, Munzel T, and Lackner KJ. Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27: 850-857, 2007.
222. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, and Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 90: 1205-1213, 2002.
223. Ueno N, Takeya R, Miyano K, Kikuchi H, and Sumimoto H. The NADPH oxidase Nox3 constitutively produces superoxide in a p22phox-dependent manner: Its regulation by oxidase organizers and activators. J Biol Chem 280: 23328-23339, 2005.
224. Van Buul JD, Fernandez-Borja M, Anthony EC, and Hordijk PL. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid. Redox Signal. 7: 308-317, 2005.
225. Vander Laan PA, Reardon CA, and Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol 24: 12-22, 2004.
226. Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, Brovkovych V, Fellin R, and Malinski T. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: Key role of L-arginine availability. Circulation 101: 1261-1266, 2000.
227. Vigone MC, Fugazzola L, Zamproni I, Passoni A, Di Candia S, Chiumello G, Persani L, and Weber G. Persistent mild hypothyroidism associated with novel sequence variants of the DUOX2 gene in two siblings. Hum Mutat 26: 395, 2005.
228. Violi F, Sanguigni V, Loffredo L, Carnevale R, Buchetti B, Finocchi A, Tesauro M, Rossi P, and Pignatelli P. Nox2 is determinant for ischemia-induced oxidative stress and arterial vasodilatation: A pilot study in patients with hereditary Nox2 deficiency. Arterioscler Thromb Vasc Biol 26: e131-132, 2006.
229. Vulcano M, Dusi S, Lissandrini D, Badolato R, Mazzi P, Riboldi E, Borroni E, Calleri A, Donini M, Plebani A, Notarangelo L, Musso T, and Sozzani S. Toll receptor-mediated regulation of NADPH oxidase in human dendritic cells. J Immunol 173: 5749-5756, 2004.
230. Wagner AH, Kohler T, Ruckschloss U, Just I, and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69, 2000.
231. Wang D, Chabrashvili T, Borrego L, Aslam S, and Umans JG. Angiotensin II infusion alters vascular function in mouse resistance vessels: Roles of O and endothelium. J Vasc Res 43: 109-119, 2006.
232. Wedgwood S and Black SM. Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 288: L480-487, 2005.
233. Wedgwood S, Dettman RW, and Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 281: L1058-1067, 2001.
234. Wilkins GM and Leake DS. The effect of inhibitors of free radical generating-enzymes on low-density lipoprotein oxidation by macrophages. Biochim Biophys Acta 1211: 69-78, 1994.
235. Wingler K, Wunsch S, Kreutz R, Rothermund L, Paul M, and Schmidt HH. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 31: 1456-1464, 2001.
236. Witztum JL and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88: 1785-1792, 1991.
237. Wolin MS, Ahmad M, Gao Q, and Gupte SA. Cytosolic NAD(P)H regulation of redox signaling and vascular oxygen sensing. Antioxid Redox Signal 9: 671-678, 2007.
238. Xu H, Goettsch C, Xia N, Horke S, Morawietz H, Forstermann U, and Li H. Differential roles of PKCalpha and PKCvarepsilon in controlling the gene expression of Nox4 in human endothelial cells. Free Radic Biol Med 44: 1656-1667, 2008.
239. Xu J, Xie Z, Reece R, Pimental D, and Zou MH. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: Role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol 26: 2688-2695, 2006.
240. Xu X, Gao X, Potter BJ, Cao JM, and Zhang C. Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol 27: 871-877, 2007.
241. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
242. Yoshida H, Quehenberger O, Kondratenko N, Green S, and Steinberg D. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 18: 794-802, 1998.
243. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beaumont FJ, and Diez J. Oxidative stress in arterial hypertension: Role of NAD(P)H oxidase. Hypertension 38: 1395-1399, 2001.
244. Zalba G, Fortuno A, Orbe J, San Jose G, Moreno MU, Belzunce M, Rodriguez JA, Beloqui O, Paramo JA, and Diez J. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: Implications for human atherosclerosis. Arterioscler Thromb Vasc Biol 27: 587-593, 2007.
245. Zandbergen F and Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 1771: 972-982, 2007.
246. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, and Daniel WG. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44: 215-222, 1999.
247. Zhang H, Luo Y, Zhang W, He Y, Dai S, Zhang R, Huang Y, Bernatchez P, Giordano FJ, Shadel G, Sessa WC, and Min W. Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol 170: 1108-1120, 2007.
248. Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, and Raij L. Reduced NAD(P)H oxidase in low renin hypertension: Link among angiotensin II, atherogenesis, and blood pressure. Hypertension 47: 81-86, 2006.
249. Zou M, Martin C, and Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 378: 707-713, 1997.